Drug Profile
BVAC B
Alternative Names: Autologous B cell and monocyte presenting HER2/neu antigen - Cellid; BVAC-BLatest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Cellid Company
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastric cancer
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for phase-I development in Gastric-cancer(Recurrent, Second-line therapy or greater) in South Korea (IV, Injection)
- 29 May 2020 Adverse events and immunogenicity data from a phase I trial in Gastric cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
- 08 Feb 2018 Cellid plans a phase I trial for Gastric cancer (Recurrent, Second-line therapy or greater) in South Korea (NCT03425773)